Market Executive Summary

The global market for Ulcerative Colitis was estimated to be worth US$ 7810 million in 2023 and is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 5.3% during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.

The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need.

Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum).

Report Scope

This report aims to provide a comprehensive presentation of the global market for Ulcerative Colitis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Ulcerative Colitis by region & country, by Type, and by Application.

The Ulcerative Colitis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ulcerative Colitis.

Global Ulcerative Colitis Companies Covered

Pfizer, Novartis, Roche, Sanofi, GSK, AstraZeneca, MSD, Johnson & Johnson, Bayer, AbbVie, Eli Lilly and Company, Amgen, Takeda Pharmaceuticals Company, Ferring Pharmaceuticals, InDeX Pharmaceuticals.

Global Ulcerative Colitis Market, Segment by Type

Oral

Injection

Global Ulcerative Colitis Market, Segment by Application

Hospital

Drugs Stores

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Ulcerative Colitis manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Ulcerative Colitis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Ulcerative Colitis in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.